Non-small cell lung cancer

Common Name(s)

Non-small cell lung cancer

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Non-small cell lung cancer" for support, advocacy or research.

Free to Breathe

Free to Breathe is a partnership of lung cancer survivors, advocates, researchers, healthcare professionals and industry leaders united in the belief that every person with lung cancer deserves a cure. Free to Breathe is dedicated to doubling lung cancer survival by 2022.

Last Updated: 16 Oct 2014

View Details
Logo
Lung Cancer Foundation of America

LCFA’s mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.

Last Updated: 28 Aug 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Non-small cell lung cancer" for support, advocacy or research.

Free to Breathe

Free to Breathe is a partnership of lung cancer survivors, advocates, researchers, healthcare professionals and industry leaders united in the belief that every person with lung cancer deserves a cure. Free to Breathe is dedicated to doubling lung cancer survival by 2022.

http://www.freetobreathe.org

Last Updated: 16 Oct 2014

View Details
Logo
Lung Cancer Foundation of America

LCFA’s mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA will work to raise both the funds and the national profile of lung cancer in order to substantially increase support of innovative and groundbreaking research efforts.

http://www.LCFAmerica.org

Last Updated: 28 Aug 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Non-small cell lung cancer" returned 4198 free, full-text research articles on human participants. First 3 results:

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
 

Author(s): Alice T Shaw, Benjamin J Solomon

Journal: N. Engl. J. Med.. 2015 Feb;372(7):683-4.

 

Last Updated: 12 Feb 2015

Go To URL
Effect of ginseng polysaccharides and dendritic cells on the balance of Th1/Th2 T helper cells in patients with non-small cell lung cancer.
 

Author(s): Junjie Ma, Huiping Liu, Xiaolong Wang

Journal: J Tradit Chin Med. 2014 Dec;34(6):641-5.

 

To investigate the effect of thorascopic administration.of ginseng polysaccharides (GPS) plus dendritic cells (DC) on T helper cell type 1/T helper cell type 2 (Th1/Th2) balance in patients with non-small cell lung cancer (NSCLC).

Last Updated: 26 Jan 2015

Go To URL
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
 

Author(s): Silvia Novello, Rolf Kaiser, Anders Mellemgaard, Jean-Yves Douillard, Sergey Orlov, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, José Barrueco, Birgit Gaschler-Markefski, Ingolf Griebsch, Michael Palmer, Martin Reck,

Journal: Eur. J. Cancer. 2015 Feb;51(3):317-26.

 

The LUME-Lung 1 trial (NCT00805194; Study 1199.13) demonstrated a significant overall survival (OS) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) and adenocarcinoma ...

Last Updated: 4 Feb 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Non-small cell lung cancer" returned 493 free, full-text review articles on human participants. First 3 results:

[Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].
 

Author(s): Shilong Song, Minghong Bi

Journal: Zhongguo Fei Ai Za Zhi. 2014 Oct;17(10):755-9.

 

Lung cancer is one of the most common malignant tumors of the world, and non-small cell lung cancer (NSCLC) makes up about 80%. The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signal pathway has pleiotropic effects on many biological processes. However, ...

Last Updated: 24 Oct 2014

Go To URL
[Advances of driver gene and targeted therapy of non-small cell lung cancer].
 

Author(s): Dan Zhang, Yan Huang, Hongyang Wang

Journal: Zhongguo Fei Ai Za Zhi. 2014 Oct;17(10):750-4.

 

Lung cancer is the leading cause of cancer-related mortality in the worldwide. The discovery of drive gene makes tumor treatment is no longer "one-size-fits-all". Targeted therapy to change the present situation of cancer drugs become "bullet" with eyes, the effect is visible and ...

Last Updated: 24 Oct 2014

Go To URL
[Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for 
non-small cell lung cancer].
 

Author(s): Cheng Lin, Xiong Chen, Jingnan Liu, Yufang Huang, Xuenong Ou-Yang

Journal: Zhongguo Fei Ai Za Zhi. 2014 Oct;17(10):734-40.

 

Lung cancer is the leading cause of cancer-related mortality worldwide. Despiting the great progress on target agents, majority of people who do not harbor a mutation could not get benefit from them. Immunotherapy, through stimulating the body's immune system to improve the antitumor ...

Last Updated: 24 Oct 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
 

Status: Recruiting

Condition Summary: Non-small Cell Lung Cancer; Advanced Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer

 

Last Updated: 9 Dec 2014

Go to URL
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
 

Status: Recruiting

Condition Summary: Cachexia; Fatigue; Pulmonary Complications; Radiation Toxicity; Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer

 

Last Updated: 17 Mar 2015

Go to URL
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
 

Status: Recruiting

Condition Summary: Non-small Cell Lung Cancer; Progression of Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Recurrent

 

Last Updated: 26 Mar 2015

Go to URL